|
1
|
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
|
Sci Transl Med
|
2010
|
6.39
|
|
2
|
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
|
Nat Genet
|
2012
|
5.28
|
|
3
|
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
|
Proc Natl Acad Sci U S A
|
2009
|
2.77
|
|
4
|
MYCN regulates oncogenic MicroRNAs in neuroblastoma.
|
Int J Cancer
|
2008
|
2.76
|
|
5
|
Retracted
Cytohesins are cytoplasmic ErbB receptor activators.
|
Cell
|
2010
|
2.74
|
|
6
|
Circulating microRNAs (miRNA) in serum of patients with prostate cancer.
|
Urology
|
2011
|
1.73
|
|
7
|
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
|
Clin Cancer Res
|
2012
|
1.65
|
|
8
|
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.
|
Mod Pathol
|
2012
|
1.50
|
|
9
|
p53 predictive value for pT1-2 N0 disease at radical cystectomy.
|
J Urol
|
2009
|
1.43
|
|
10
|
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
|
J Clin Invest
|
2013
|
1.41
|
|
11
|
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
|
Urology
|
2008
|
1.24
|
|
12
|
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
|
Clin Cancer Res
|
2005
|
1.22
|
|
13
|
A framework for identification of actionable cancer genome dependencies in small cell lung cancer.
|
Proc Natl Acad Sci U S A
|
2012
|
1.21
|
|
14
|
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
|
J Natl Cancer Inst
|
2009
|
1.21
|
|
15
|
CD74-NRG1 fusions in lung adenocarcinoma.
|
Cancer Discov
|
2014
|
1.19
|
|
16
|
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
|
Cancer Discov
|
2013
|
1.18
|
|
17
|
CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
|
Prostate
|
2008
|
1.16
|
|
18
|
Global levels of histone modifications predict prostate cancer recurrence.
|
Prostate
|
2010
|
1.11
|
|
19
|
Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
|
Eur Urol
|
2006
|
1.07
|
|
20
|
Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators.
|
Int J Cancer
|
2008
|
1.00
|
|
21
|
MicroRNAs in the pathogenesis of neuroblastoma.
|
Cancer Lett
|
2008
|
1.00
|
|
22
|
Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
|
J Hepatol
|
2013
|
0.98
|
|
23
|
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
|
Histochem Cell Biol
|
2006
|
0.97
|
|
24
|
Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.
|
Int J Cancer
|
2011
|
0.95
|
|
25
|
Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.
|
J Cancer Res Clin Oncol
|
2008
|
0.95
|
|
26
|
Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer.
|
BJU Int
|
2011
|
0.94
|
|
27
|
Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
|
J Urol
|
2007
|
0.94
|
|
28
|
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC.
|
Cancer Discov
|
2014
|
0.93
|
|
29
|
Mast cells play a protumorigenic role in primary cutaneous lymphoma.
|
Blood
|
2012
|
0.93
|
|
30
|
Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
|
Urol Oncol
|
2010
|
0.93
|
|
31
|
The role of molecular diagnostics in cancer diagnosis and treatment.
|
Onkologie
|
2012
|
0.93
|
|
32
|
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
|
Int J Cancer
|
2013
|
0.92
|
|
33
|
Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.
|
Am J Pathol
|
2006
|
0.91
|
|
34
|
Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer.
|
Anticancer Res
|
2010
|
0.89
|
|
35
|
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
|
J Thorac Oncol
|
2015
|
0.89
|
|
36
|
Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer.
|
Cancer Invest
|
2011
|
0.87
|
|
37
|
Four-and-a-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration.
|
J Immunol
|
2010
|
0.86
|
|
38
|
Alterations of global histone H4K20 methylation during prostate carcinogenesis.
|
BMC Urol
|
2012
|
0.86
|
|
39
|
Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
|
Int J Mol Med
|
2010
|
0.85
|
|
40
|
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
|
J Thorac Oncol
|
2015
|
0.82
|
|
41
|
Web-based database for the management of tissue specimens in a transregional histological research facility.
|
Diagn Pathol
|
2011
|
0.81
|
|
42
|
Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer.
|
Urol Int
|
2014
|
0.81
|
|
43
|
Loss of the keratin cytoskeleton is not sufficient to induce epithelial mesenchymal transition in a novel KRAS driven sporadic lung cancer mouse model.
|
PLoS One
|
2013
|
0.81
|
|
44
|
Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues.
|
J Clin Pathol
|
2013
|
0.80
|
|
45
|
Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
|
PLoS One
|
2012
|
0.80
|
|
46
|
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
|
Acta Neuropathol Commun
|
2013
|
0.77
|
|
47
|
Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
|
Diagn Pathol
|
2014
|
0.75
|
|
48
|
Retraction Notice to: Cytohesins Are Cytoplasmic ErbB Receptor Activators.
|
Cell
|
2016
|
0.75
|
|
49
|
Correction: Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.
|
J Exp Med
|
2017
|
0.75
|
|
50
|
Successful AZD9291 Therapy Based on Circulating T790M.
|
J Thorac Oncol
|
2015
|
0.75
|
|
51
|
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.
|
Oncol Res Treat
|
2015
|
0.75
|